The Mechanisms of Resistance in Breast Cancer
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the mechanisms of resistance in breast cancer.
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the mechanisms of resistance in breast cancer.
Clinical Pearls
The oncology community has discovered the mechanisms of resistance for several types of cancers, Sledge says. The next step is to figure out ways around them. A good example of this, Sledge notes is that when a patient becomes resistant to an aromatase inhibitor, mTOR inhibitors (such as everolimus) can overcome mechanisms of resistance. The oncology community now needs to apply known information to the entire breast cancer puzzle.
- The mechanisms of resistance for several types of cancers are known
- When a patient becomes resistant to an aromatase inhibitor, mTOR inhibitors can overcome mechanisms of resistance
- The next step, Sledge says, is to apply known information to the breast cancer puzzle
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
